6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.

      Journal of clinical oncology : official journal of the American Society of Clinical Oncology
      Adolescent, Adult, Amifostine, adverse effects, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Cerebellar Neoplasms, drug therapy, radiotherapy, surgery, Child, Child, Preschool, Cisplatin, administration & dosage, Cranial Irradiation, Cyclophosphamide, Disease-Free Survival, Female, Hearing Aids, Hearing Loss, chemically induced, prevention & control, rehabilitation, Humans, Male, Medulloblastoma, Prospective Studies, Risk Assessment, Stem Cell Transplantation, Time Factors, Treatment Outcome, Vincristine

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To determine the role of amifostine as a protectant against cisplatin-induced ototoxicity in patients with average-risk (AR) medulloblastoma treated with craniospinal radiotherapy and four cycles of cisplatin-based, dose-intense chemotherapy and stem-cell rescue. The primary objective was to determine whether, in patients with AR medulloblastoma (n = 62), amifostine would decrease the need for hearing aids (defined as >or= grade 3 ototoxicity in one ear) compared with a control group (n = 35), 1 year from initiating treatment. Ninety-seven patients received craniospinal irradiation (23.4 Gy) followed by 55.8 Gy to the primary tumor bed using three-dimensional conformal technique, and four cycles of high-dose cyclophosphamide (4,000 mg/m(2)/cycle), cisplatin (75 mg/m(2)/cycle), and vincristine (two 1.5 mg/m(2) doses/cycle) and stem-cell rescue. When used, amifostine (600 mg/m(2)/dose) was administered as a bolus immediately before and 3 hours into the cisplatin infusion. The median age of the 97 patients was 8.7 years (range, 3.2 to 20.2 years). The study and control groups were similar in age and sex distribution. Amifostine was well-tolerated. One year after treatment initiation, 13 patients (37.1%) in the control group versus nine (14.5%; one-sided chi(2) test P = .005) of the amifostine-treated patients had at least grade 3 ototoxicity, requiring hearing aid in at least one ear. Amifostine administered before and during the cisplatin infusion can significantly reduce the risk of severe ototoxicity in patients with AR medulloblastoma receiving dose-intense chemotherapy.

          Related collections

          Author and article information

          Comments

          Comment on this article